Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 12571 entries
Sorted by: Best Match Show Resources per page
Morphine use in cancer surgery.

Frontiers in pharmacology

Afsharimani B, Cabot PJ, Parat MO.
PMID: 21852973
Front Pharmacol. 2011 Aug 08;2:46. doi: 10.3389/fphar.2011.00046. eCollection 2011.

Morphine is the core of perioperative pain management. However, when it comes to cancer surgery the possibility that this drug might affect tumor recurrence and metastasis has raised concerns. The results of two recent retrospective clinical trials indicated that...

Cite
Afsharimani B, Cabot PJ, Parat MO. Morphine use in cancer surgery. Front Pharmacol. 2011;2:46doi: 10.3389/fphar.2011.00046.
Afsharimani, B., Cabot, P. J., & Parat, M. O. (2011). Morphine use in cancer surgery. Frontiers in pharmacology, 246. https://doi.org/10.3389/fphar.2011.00046
Afsharimani, Banafsheh, et al. "Morphine use in cancer surgery." Frontiers in pharmacology vol. 2 (2011): 46. doi: https://doi.org/10.3389/fphar.2011.00046
Afsharimani B, Cabot PJ, Parat MO. Morphine use in cancer surgery. Front Pharmacol. 2011 Aug 08;2:46. doi: 10.3389/fphar.2011.00046. eCollection 2011. PMID: 21852973; PMCID: PMC3151591.
Copy Download .nbib Format: NLM
Strategies for developing novel therapeutics for sensorineural hearing loss.

Frontiers in pharmacology

Nakagawa T.
PMID: 25278894
Front Pharmacol. 2014 Sep 16;5:206. doi: 10.3389/fphar.2014.00206. eCollection 2014.

Sensorineural hearing loss (SNHL) is a common disability in the world; however, at present, options for the pharmacological treatment of SNHL are very limited. Previous studies involving human temporal bone analyses have revealed that the degeneration of the cochlea...

Cite
Nakagawa T. Strategies for developing novel therapeutics for sensorineural hearing loss. Front Pharmacol. 2014;5:206doi: 10.3389/fphar.2014.00206.
Nakagawa, T. (2014). Strategies for developing novel therapeutics for sensorineural hearing loss. Frontiers in pharmacology, 5206. https://doi.org/10.3389/fphar.2014.00206
Nakagawa, Takayuki. "Strategies for developing novel therapeutics for sensorineural hearing loss." Frontiers in pharmacology vol. 5 (2014): 206. doi: https://doi.org/10.3389/fphar.2014.00206
Nakagawa T. Strategies for developing novel therapeutics for sensorineural hearing loss. Front Pharmacol. 2014 Sep 16;5:206. doi: 10.3389/fphar.2014.00206. eCollection 2014. PMID: 25278894; PMCID: PMC4165348.
Copy Download .nbib Format: NLM
Calcium and IP3 dynamics in cardiac myocytes: experimental and computational perspectives and approaches.

Frontiers in pharmacology

Hohendanner F, McCulloch AD, Blatter LA, Michailova AP.
PMID: 24639654
Front Pharmacol. 2014 Mar 06;5:35. doi: 10.3389/fphar.2014.00035. eCollection 2014.

Calcium plays a crucial role in excitation-contraction coupling (ECC), but it is also a pivotal second messenger activating Ca(2+)-dependent transcription factors in a process termed excitation-transcription coupling (ETC). Evidence accumulated over the past decade indicates a pivotal role of...

Cite
Hohendanner F, McCulloch AD, Blatter LA, et al. Calcium and IP3 dynamics in cardiac myocytes: experimental and computational perspectives and approaches. Front Pharmacol. 2014;5:35doi: 10.3389/fphar.2014.00035.
Hohendanner, F., McCulloch, A. D., Blatter, L. A., & Michailova, A. P. (2014). Calcium and IP3 dynamics in cardiac myocytes: experimental and computational perspectives and approaches. Frontiers in pharmacology, 535. https://doi.org/10.3389/fphar.2014.00035
Hohendanner, Felix, et al. "Calcium and IP3 dynamics in cardiac myocytes: experimental and computational perspectives and approaches." Frontiers in pharmacology vol. 5 (2014): 35. doi: https://doi.org/10.3389/fphar.2014.00035
Hohendanner F, McCulloch AD, Blatter LA, Michailova AP. Calcium and IP3 dynamics in cardiac myocytes: experimental and computational perspectives and approaches. Front Pharmacol. 2014 Mar 06;5:35. doi: 10.3389/fphar.2014.00035. eCollection 2014. PMID: 24639654; PMCID: PMC3944219.
Copy Download .nbib Format: NLM
Physiological mechanisms of vascular response induced by shear stress and effect of exercise in systemic and placental circulation.

Frontiers in pharmacology

Rodríguez I, González M.
PMID: 25278895
Front Pharmacol. 2014 Sep 16;5:209. doi: 10.3389/fphar.2014.00209. eCollection 2014.

Physiological vascular function regulation is essential for cardiovascular health and depends on adequate control of molecular mechanisms triggered by endothelial cells in response to mechanical and chemical stimuli induced by blood flow. Endothelial dysfunction is one of the main...

Cite
Rodríguez I, González M. Physiological mechanisms of vascular response induced by shear stress and effect of exercise in systemic and placental circulation. Front Pharmacol. 2014;5:209doi: 10.3389/fphar.2014.00209.
Rodríguez, I., & González, M. (2014). Physiological mechanisms of vascular response induced by shear stress and effect of exercise in systemic and placental circulation. Frontiers in pharmacology, 5209. https://doi.org/10.3389/fphar.2014.00209
Rodríguez, Iván, and González, Marcelo. "Physiological mechanisms of vascular response induced by shear stress and effect of exercise in systemic and placental circulation." Frontiers in pharmacology vol. 5 (2014): 209. doi: https://doi.org/10.3389/fphar.2014.00209
Rodríguez I, González M. Physiological mechanisms of vascular response induced by shear stress and effect of exercise in systemic and placental circulation. Front Pharmacol. 2014 Sep 16;5:209. doi: 10.3389/fphar.2014.00209. eCollection 2014. PMID: 25278895; PMCID: PMC4165280.
Copy Download .nbib Format: NLM
Aldo-Keto Reductases 1B in Endocrinology and Metabolism.

Frontiers in pharmacology

Pastel E, Pointud JC, Volat F, Martinez A, Lefrançois-Martinez AM.
PMID: 22876234
Front Pharmacol. 2012 Aug 02;3:148. doi: 10.3389/fphar.2012.00148. eCollection 2012.

The aldose reductase (AR; human AKR1B1/mouse Akr1b3) has been the focus of many research because of its role in diabetic complications. The starting point of these alterations is the massive entry of glucose in polyol pathway where it is...

Cite
Pastel E, Pointud JC, Volat F, et al. Aldo-Keto Reductases 1B in Endocrinology and Metabolism. Front Pharmacol. 2012;3:148doi: 10.3389/fphar.2012.00148.
Pastel, E., Pointud, J. C., Volat, F., Martinez, A., & Lefrançois-Martinez, A. M. (2012). Aldo-Keto Reductases 1B in Endocrinology and Metabolism. Frontiers in pharmacology, 3148. https://doi.org/10.3389/fphar.2012.00148
Pastel, Emilie, et al. "Aldo-Keto Reductases 1B in Endocrinology and Metabolism." Frontiers in pharmacology vol. 3 (2012): 148. doi: https://doi.org/10.3389/fphar.2012.00148
Pastel E, Pointud JC, Volat F, Martinez A, Lefrançois-Martinez AM. Aldo-Keto Reductases 1B in Endocrinology and Metabolism. Front Pharmacol. 2012 Aug 02;3:148. doi: 10.3389/fphar.2012.00148. eCollection 2012. PMID: 22876234; PMCID: PMC3410611.
Copy Download .nbib Format: NLM
C-C chemokine receptor-7 mediated endocytosis of antibody cargoes into intact cells.

Frontiers in pharmacology

Charest-Morin X, Pépin R, Gagné-Henley A, Morissette G, Lodge R, Marceau F.
PMID: 24068998
Front Pharmacol. 2013 Sep 24;4:122. doi: 10.3389/fphar.2013.00122. eCollection 2013.

The C-C chemokine receptor-7 (CCR7) is a G protein coupled receptor that has a role in leukocyte homing, but that is also expressed in aggressive tumor cells. Preclinical research supports that CCR7 is a valid target in oncology. In...

Cite
Charest-Morin X, Pépin R, Gagné-Henley A, et al. C-C chemokine receptor-7 mediated endocytosis of antibody cargoes into intact cells. Front Pharmacol. 2013;4:122doi: 10.3389/fphar.2013.00122.
Charest-Morin, X., Pépin, R., Gagné-Henley, A., Morissette, G., Lodge, R., & Marceau, F. (2013). C-C chemokine receptor-7 mediated endocytosis of antibody cargoes into intact cells. Frontiers in pharmacology, 4122. https://doi.org/10.3389/fphar.2013.00122
Charest-Morin, Xavier, et al. "C-C chemokine receptor-7 mediated endocytosis of antibody cargoes into intact cells." Frontiers in pharmacology vol. 4 (2013): 122. doi: https://doi.org/10.3389/fphar.2013.00122
Charest-Morin X, Pépin R, Gagné-Henley A, Morissette G, Lodge R, Marceau F. C-C chemokine receptor-7 mediated endocytosis of antibody cargoes into intact cells. Front Pharmacol. 2013 Sep 24;4:122. doi: 10.3389/fphar.2013.00122. eCollection 2013. PMID: 24068998; PMCID: PMC3781320.
Copy Download .nbib Format: NLM
Beyond osteogenesis: an in vitro comparison of the potentials of six bone morphogenetic proteins.

Frontiers in pharmacology

Rivera JC, Strohbach CA, Wenke JC, Rathbone CR.
PMID: 24101902
Front Pharmacol. 2013 Oct 01;4:125. doi: 10.3389/fphar.2013.00125. eCollection 2013.

Bone morphogenetic proteins (BMPs) other than the clinically available BMP-2 and BMP-7 may be useful for improving fracture healing through both increasing osteogenesis and creating a favorable healing environment by altering cytokine release by endogenous cells. Given the spectrum...

Cite
Rivera JC, Strohbach CA, Wenke JC, et al. Beyond osteogenesis: an in vitro comparison of the potentials of six bone morphogenetic proteins. Front Pharmacol. 2013;4:125doi: 10.3389/fphar.2013.00125.
Rivera, J. C., Strohbach, C. A., Wenke, J. C., & Rathbone, C. R. (2013). Beyond osteogenesis: an in vitro comparison of the potentials of six bone morphogenetic proteins. Frontiers in pharmacology, 4125. https://doi.org/10.3389/fphar.2013.00125
Rivera, Jessica C, et al. "Beyond osteogenesis: an in vitro comparison of the potentials of six bone morphogenetic proteins." Frontiers in pharmacology vol. 4 (2013): 125. doi: https://doi.org/10.3389/fphar.2013.00125
Rivera JC, Strohbach CA, Wenke JC, Rathbone CR. Beyond osteogenesis: an in vitro comparison of the potentials of six bone morphogenetic proteins. Front Pharmacol. 2013 Oct 01;4:125. doi: 10.3389/fphar.2013.00125. eCollection 2013. PMID: 24101902; PMCID: PMC3787247.
Copy Download .nbib Format: NLM
Perlecan and the blood-brain barrier: beneficial proteolysis?.

Frontiers in pharmacology

Roberts J, Kahle MP, Bix GJ.
PMID: 22936915
Front Pharmacol. 2012 Aug 23;3:155. doi: 10.3389/fphar.2012.00155. eCollection 2012.

The cerebral microvasculature is important for maintaining brain homeostasis. This is achieved via the blood-brain barrier (BBB), composed of endothelial cells with specialized tight junctions, astrocytes, and a basement membrane (BM). Prominent components of the BM extracellular matrix (ECM)...

Cite
Roberts J, Kahle MP, Bix GJ. Perlecan and the blood-brain barrier: beneficial proteolysis?. Front Pharmacol. 2012;3:155doi: 10.3389/fphar.2012.00155.
Roberts, J., Kahle, M. P., & Bix, G. J. (2012). Perlecan and the blood-brain barrier: beneficial proteolysis?. Frontiers in pharmacology, 3155. https://doi.org/10.3389/fphar.2012.00155
Roberts, Jill, et al. "Perlecan and the blood-brain barrier: beneficial proteolysis?." Frontiers in pharmacology vol. 3 (2012): 155. doi: https://doi.org/10.3389/fphar.2012.00155
Roberts J, Kahle MP, Bix GJ. Perlecan and the blood-brain barrier: beneficial proteolysis?. Front Pharmacol. 2012 Aug 23;3:155. doi: 10.3389/fphar.2012.00155. eCollection 2012. PMID: 22936915; PMCID: PMC3425914.
Copy Download .nbib Format: NLM
Expression Profiling of Solute Carrier Gene Families at the Blood-CSF Barrier.

Frontiers in pharmacology

Ho HT, Dahlin A, Wang J.
PMID: 22936914
Front Pharmacol. 2012 Aug 24;3:154. doi: 10.3389/fphar.2012.00154. eCollection 2012.

The choroid plexus (CP) is a highly vascularized tissue in the brain ventricles and acts as the blood-cerebrospinal fluid (CSF) barrier (BCSFB). A main function of the CP is to secrete CSF, which is accomplished by active transport of...

Cite
Ho HT, Dahlin A, Wang J. Expression Profiling of Solute Carrier Gene Families at the Blood-CSF Barrier. Front Pharmacol. 2012;3:154doi: 10.3389/fphar.2012.00154.
Ho, H. T., Dahlin, A., & Wang, J. (2012). Expression Profiling of Solute Carrier Gene Families at the Blood-CSF Barrier. Frontiers in pharmacology, 3154. https://doi.org/10.3389/fphar.2012.00154
Ho, Horace T B, et al. "Expression Profiling of Solute Carrier Gene Families at the Blood-CSF Barrier." Frontiers in pharmacology vol. 3 (2012): 154. doi: https://doi.org/10.3389/fphar.2012.00154
Ho HT, Dahlin A, Wang J. Expression Profiling of Solute Carrier Gene Families at the Blood-CSF Barrier. Front Pharmacol. 2012 Aug 24;3:154. doi: 10.3389/fphar.2012.00154. eCollection 2012. PMID: 22936914; PMCID: PMC3426838.
Copy Download .nbib Format: NLM
Maternally sequestered therapeutic polypeptides - a new approach for the management of preeclampsia.

Frontiers in pharmacology

Bidwell GL, George EM.
PMID: 25249978
Front Pharmacol. 2014 Sep 05;5:201. doi: 10.3389/fphar.2014.00201. eCollection 2014.

The last several decades have seen intensive research into the molecular mechanisms underlying the symptoms of preeclampsia. While the underlying cause of preeclampsia is believed to be defective placental development and resulting placental ischemia, it is only recently that...

Cite
Bidwell GL, George EM. Maternally sequestered therapeutic polypeptides - a new approach for the management of preeclampsia. Front Pharmacol. 2014;5:201doi: 10.3389/fphar.2014.00201.
Bidwell, G. L., & George, E. M. (2014). Maternally sequestered therapeutic polypeptides - a new approach for the management of preeclampsia. Frontiers in pharmacology, 5201. https://doi.org/10.3389/fphar.2014.00201
Bidwell, Gene L, and George, Eric M. "Maternally sequestered therapeutic polypeptides - a new approach for the management of preeclampsia." Frontiers in pharmacology vol. 5 (2014): 201. doi: https://doi.org/10.3389/fphar.2014.00201
Bidwell GL, George EM. Maternally sequestered therapeutic polypeptides - a new approach for the management of preeclampsia. Front Pharmacol. 2014 Sep 05;5:201. doi: 10.3389/fphar.2014.00201. eCollection 2014. PMID: 25249978; PMCID: PMC4155872.
Copy Download .nbib Format: NLM
The role of iron in neurodegenerative disorders: insights and opportunities with synchrotron light.

Frontiers in pharmacology

Collingwood JF, Davidson MR.
PMID: 25191270
Front Pharmacol. 2014 Aug 19;5:191. doi: 10.3389/fphar.2014.00191. eCollection 2014.

There is evidence for iron dysregulation in many forms of disease, including a broad spectrum of neurodegenerative disorders. In order to advance our understanding of the pathophysiological role of iron, it is helpful to be able to determine in...

Cite
Collingwood JF, Davidson MR. The role of iron in neurodegenerative disorders: insights and opportunities with synchrotron light. Front Pharmacol. 2014;5:191doi: 10.3389/fphar.2014.00191.
Collingwood, J. F., & Davidson, M. R. (2014). The role of iron in neurodegenerative disorders: insights and opportunities with synchrotron light. Frontiers in pharmacology, 5191. https://doi.org/10.3389/fphar.2014.00191
Collingwood, Joanna F, and Davidson, Mark R. "The role of iron in neurodegenerative disorders: insights and opportunities with synchrotron light." Frontiers in pharmacology vol. 5 (2014): 191. doi: https://doi.org/10.3389/fphar.2014.00191
Collingwood JF, Davidson MR. The role of iron in neurodegenerative disorders: insights and opportunities with synchrotron light. Front Pharmacol. 2014 Aug 19;5:191. doi: 10.3389/fphar.2014.00191. eCollection 2014. PMID: 25191270; PMCID: PMC4137459.
Copy Download .nbib Format: NLM
Dual Regulation of Voltage-Sensitive Ion Channels by PIP(2).

Frontiers in pharmacology

Rodríguez-Menchaca AA, Adney SK, Zhou L, Logothetis DE.
PMID: 23055973
Front Pharmacol. 2012 Sep 25;3:170. doi: 10.3389/fphar.2012.00170. eCollection 2012.

Over the past 16 years, there has been an impressive number of ion channels shown to be sensitive to the major phosphoinositide in the plasma membrane, phosphatidylinositol 4,5-bisphosphate (PIP(2)). Among them are voltage-gated channels, which are crucial for both...

Cite
Rodríguez-Menchaca AA, Adney SK, Zhou L, et al. Dual Regulation of Voltage-Sensitive Ion Channels by PIP(2). Front Pharmacol. 2012;3:170doi: 10.3389/fphar.2012.00170.
Rodríguez-Menchaca, A. A., Adney, S. K., Zhou, L., & Logothetis, D. E. (2012). Dual Regulation of Voltage-Sensitive Ion Channels by PIP(2). Frontiers in pharmacology, 3170. https://doi.org/10.3389/fphar.2012.00170
Rodríguez-Menchaca, Aldo A, et al. "Dual Regulation of Voltage-Sensitive Ion Channels by PIP(2)." Frontiers in pharmacology vol. 3 (2012): 170. doi: https://doi.org/10.3389/fphar.2012.00170
Rodríguez-Menchaca AA, Adney SK, Zhou L, Logothetis DE. Dual Regulation of Voltage-Sensitive Ion Channels by PIP(2). Front Pharmacol. 2012 Sep 25;3:170. doi: 10.3389/fphar.2012.00170. eCollection 2012. PMID: 23055973; PMCID: PMC3456799.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 12571 entries